NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
Clinical Trials
565 trialsNCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07515469 2026-04-07
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT06553885 2026-04-01
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07062055 2026-04-01
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT03727633 2026-03-31
LIDA-BII
University Hospital, Montpellier
Phase 2 Terminated
NCT07312292 2026-03-30
RADIANT
UMC Utrecht
Phase 2 Recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT06902246 2026-03-27
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07331883 2026-03-27
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07495579 2026-03-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07493668 2026-03-25
FLEX-HCC
CHA University
Phase 2 Not yet recruiting
NCT03753659 2026-03-23
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT07483359 2026-03-19
CONV3RSION
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT07010497 2026-03-18
IAPETUS
Asan Medical Center
Phase 2 Recruiting
NCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT05901519 2026-03-13
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06218420 2026-03-03
TRANSRAD-01
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT06789848 2026-02-27
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07422753 2026-02-20
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05669339 2026-02-18
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
NCT06851104 2026-02-18
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Guangxi Medical University
Phase 2 Terminated
NCT07412054 2026-02-17
BLP-HCC
Fudan University
Phase 2 Not yet recruiting
NCT07413354 2026-02-17
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT03519997 2026-02-11
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05176223 2026-02-05
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT07380633 2026-02-02
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05113186 2026-01-29
LENVABLA
Assistance Publique - Hôpitaux de Paris
Phase 2 Active not recruiting
NCT07174570 2026-01-28
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Emory University
Phase 2 Recruiting
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT04550481 2026-01-21
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Northwestern University
Phase 2 Active not recruiting
NCT05366829 2026-01-20
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Rutgers, The State University of New Jersey
Phase 2 Recruiting